![conference banner](/images/conference-banner.jpeg)
Abstract
The development of oral insulin using the eligen(®) technology represents a significant advance in insulin administration which is expected to improve the quality of life of diabetic patients. As clinical studies progress, a great deal of interest has focused on the process by which this technology enables insulin absorption from the intestinal lumen into the bloodstream. The eligen(®) technology employs low molecular weight compounds (termed drug delivery agents or carriers) which interact weakly and non-covalently with insulin, increasing its lipophilicity and thereby its ability to cross the gastrointestinal epithelium. In this study we investigated the mechanism of insulin absorption across caco-2 cell monolayers with one of these drug delivery agents, N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC). Our results show that SNAC increases insulin permeability approximately ten fold across cell monolayers and does so without affecting mannitol permeability or disrupting cell membranes. Confocal microscopy and immunocytochemistry revealed that insulin is transported transcellularly without detectable alteration of the tight junctions between adjacent cells. SNAC also appears to play some role in protecting insulin from proteolytic degradation, potentially allowing for more intact insulin to be available at the site of absorption.
Keywords: oral insulin, caco-2 cells, transcellular absorption, occludin, circular dichroism
Current Drug Delivery
Title: Oral Delivery of Insulin with the eligen(®) Technology: Mechanistic Studies
Volume: 2 Issue: 2
Author(s): Dmitry Malkov, Robert Angelo, Huai-zhen Wang, Elizabeth Flanders, Heather Tang and Isabel Gomez-Orellana
Affiliation:
Keywords: oral insulin, caco-2 cells, transcellular absorption, occludin, circular dichroism
Abstract: The development of oral insulin using the eligen(®) technology represents a significant advance in insulin administration which is expected to improve the quality of life of diabetic patients. As clinical studies progress, a great deal of interest has focused on the process by which this technology enables insulin absorption from the intestinal lumen into the bloodstream. The eligen(®) technology employs low molecular weight compounds (termed drug delivery agents or carriers) which interact weakly and non-covalently with insulin, increasing its lipophilicity and thereby its ability to cross the gastrointestinal epithelium. In this study we investigated the mechanism of insulin absorption across caco-2 cell monolayers with one of these drug delivery agents, N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC). Our results show that SNAC increases insulin permeability approximately ten fold across cell monolayers and does so without affecting mannitol permeability or disrupting cell membranes. Confocal microscopy and immunocytochemistry revealed that insulin is transported transcellularly without detectable alteration of the tight junctions between adjacent cells. SNAC also appears to play some role in protecting insulin from proteolytic degradation, potentially allowing for more intact insulin to be available at the site of absorption.
Export Options
About this article
Cite this article as:
Malkov Dmitry, Angelo Robert, Wang Huai-zhen, Flanders Elizabeth, Tang Heather and Gomez-Orellana Isabel, Oral Delivery of Insulin with the eligen(®) Technology: Mechanistic Studies, Current Drug Delivery 2005; 2 (2) . https://dx.doi.org/10.2174/1567201053586001
DOI https://dx.doi.org/10.2174/1567201053586001 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Role of Vitamin A in T Cell Homing to the Gut
Current Immunology Reviews (Discontinued) Cow’s Milk Allergy: Where have we Come from and where are we Going?
Endocrine, Metabolic & Immune Disorders - Drug Targets Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Current Trends in the Development of Electrochemical Biosensor for Detecting Analytes from Sweat
Current Medicinal Chemistry Colorectal Cancer – Increased Multidimensional Understanding of the Molecular Genesis
Current Cancer Therapy Reviews De-Risking Bio-therapeutics for Possible Drug Interactions Using Cryopreserved Human Hepatocytes
Current Drug Metabolism Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Medicinal Chemistry Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology Mesenchymal Stem Cells: Use in Cartilage Repair
Current Rheumatology Reviews Pentosidine, an Advanced Glycation Endproduct, and Arthritis
Current Rheumatology Reviews The Paracrine Role Played by Interleukin-1α in the Testis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Anti-cancer Scopes and Associated Mechanisms of Scutellaria Extract and Flavonoid Wogonin
Current Cancer Therapy Reviews The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Nuclear Receptors CAR and PXR in Metabolism and Elimination of Drugs
Current Pharmacogenomics The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets